CD274 and melanoma: The 12‐month recurrence‐free survival rate for pembrolizumab treatment in 853 resected stage III melanoma patients with PD‐L1 positive tumors was 77.1%, whereas in the placebo group, the 12‐month recurrence‐free survival rate was 62.6%.